Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
With
National Heart, Lung, and Blood Institute (NHLBI)
This study (Study 3) will recruit 9 subjects from NCT02133872 (Study1) who will agree to undergo additional autonomic testing and imaging studies at baseline and after 6 months of study treatment. Specialized imaging of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning will be conducted at the Montreal Neurological Institute, in Montreal Canada.
For this study (Study 3) we include participants being enrolled Study 1 and/or participants who have completed participation in Study 1 and have not taken minocycline for 2 months will be approached to enroll in Study 3.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects participating in Study 1 will be eligible to participate.
(For Study 3 Participants only) Willing to travel to Montreal, Canada for specialized imaging of the participant's brain using magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, Autonomic Nervous System Testing and blood drawing- if participant qualifies
No diagnosis of neurogenic (treatment-resistant) hypertension.
Not treated with minocycline.
Willing to travel to Montreal, Canada for brain imaging and testing.
Able to provide informed consent.
You may not be if
Female participants with positive pregnancy test.
Female participants with positive pregnancy test.
Clareo Health | Study 3: Minocycline Decreases Microglia Activation
